The outlook of companies tied to Viagra's legacy presents a complex investment scenario . While the initial surge generated substantial returns , generic copies have significantly diminished sales . Investing in related pharmaceutical companies now requires a discerning assessment of proprietary protection , evolving patient changes, and the possib